about
Non-nucleoside inhibitors of the hepatitis C virus NS5B RNA-dependant RNA polymerase: 2-Aryl-3-heteroaryl-1,3-thiazolidin-4-one derivativesModified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesCharacterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic miceStructure-activity relationship studies on clinically relevant HIV-1 NNRTIs.Chemometrics tools used in analytical chemistry: an overview.A novel integrase targeting agent to explore the future prospective of HIV eradication: dolutegravir.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Riociguat as a treatment regime for pulmonary arterial hypertension: a review.Recent advances in the chemistry and biology of benzothiazoles.Recent advances in polymer drug conjugates.Polysaccharides based nanomaterials for targeted anti-cancer drug delivery.Medicinal Attributes of Imidazo[1,2-a]pyridine Derivatives: An Update.Chemistry and Bioactivities of Aristeromycins: An Overview.Synthetic and Medicinal Prospective of Structurally Modified Curcumins.Design, synthesis and ex-vivo release studies of colon-specific polyphosphazene-anticancer drug conjugates.ICP-MS: Analytical Method for Identification and Detection of Elemental Impurities.Recent synthetic and medicinal perspectives of dihydropyrimidinones: A review.Recent synthetic and medicinal perspectives of tryptanthrin.2-(2,6-Dihalo-phenyl)-3-heteroaryl-2-ylmethyl-1, 3-thiazolidin-4-ones: anti-HIV agents.Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.Simultaneous Estimation of Hydrochlorothiazide, Hydralazine Hydrochloride, and Reserpine Using PCA, NAS, and NAS-PCA.Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents.Synthesis and QSAR studies on thiazolidinones as anti-HIV agents.Mechanism of Adefovir, Tenofovir and Entecavir Resistance: Molecular Modeling Studies of How A Novel Anti-HBV Agent (FMCA) Can Overcome the Drug Resistance.Synthesis and antiviral activity of cyclopropyl-spirocarbocyclic adenosine, (4R,5S,6R,7R)-4-(6-amino-9H-purin-9-yl)-7-(hydroxymethyl)spiro[2.4]heptane-5,6-diol against hepatitis C virus.2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.Synthetic and medicinal perspective of thiazolidinones: A review.Application of RP-HPLC method in dissolution testing and statistical evaluation by NASSAM for simultaneous estimation of tertiary combined dosages forms.Natural product inspired design and synthesis of β-carboline and γ-lactone based molecular hybrids.Chemometrics: A new scenario in herbal drug standardization.Molecular Docking Studies on Isocytosine Analogues as Xanthine Oxidase Inhibitors.Water-Promoted Regiospecific Azidolysis and Copper-Catalyzed Azide-Alkyne Cycloaddition: One-Pot Synthesis of 3-Hydroxy-1-alkyl-3-[(4-aryl/alkyl-1H-1,2,3-triazol-1-yl)methyl]indolin-2-ones.Natural products and their derivatives as cyclooxygenase-2 inhibitorsEnasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid LeukemiaMolecular docking studies on 4-thiazolidinones as HIV-1 RT inhibitorsTopological descriptors in modeling the HIV inhibitory activity of 2-aryl-3-pyridyl-thiazolidin-4-onesSynthesis of entecavir and its novel class of analogsSynthesis and characterization of 3β-substituted amides of 17a-aza-D-homo- 4-androsten-17-one as potent 5α-reductase inhibitors and antimicrobial agentsApplications of various analytical techniques in quality control of pharmaceutical excipientsDrug metabolizing enzymes and their inhibitors' role in cancer resistance
P50
Q27487508-5A165E3C-9D41-495D-AE7D-629AEFE2B4B1Q33653229-84D35817-5ADD-4C58-B9C8-934775CB9FD7Q35182714-613A3725-6E81-4278-8B5B-69EF85E6DBEEQ38045449-8A061396-F63A-4AA8-85AF-FAEA6CE74539Q38204023-124FB747-C291-4F06-B992-3DC8D4B28F5CQ38238224-BF83A370-ABBD-4AA2-B35D-E44030C18E7DQ38247428-6F0CCFFB-A3EB-4B4A-A4E6-83F0895D42D5Q38255515-3570F737-3D40-4E47-AA86-AFEF175AAAA9Q38355999-7C0A3750-A355-40A5-9840-1922CB9CB44AQ38488805-5E4E061B-A9C8-441F-AA24-6CD2861EDC7CQ38794160-B4AC0F3A-21CF-4014-8886-B9C39C4E5957Q38826854-782D08F5-B233-46F1-8F47-3B2EB207CE91Q38826858-4B97E680-D735-49E1-9A1D-750407674B89Q38859926-D139FEBE-BBE4-4C07-AC36-CA85CF125AD2Q39036029-7C6685AE-AB65-487A-A719-D0FA6F1BB17BQ39047352-AA8A886C-F8D3-4626-9507-EEB4DC954BB3Q39200599-BC36823C-5E72-49F6-86F5-25C4DC9E515FQ39442451-2394AA07-0CEA-42B2-A251-9FC580F05234Q39961828-A1E01058-C0D1-4F1A-8C01-D3D4FCDCEF23Q40017683-1A809986-C74D-4A5F-8821-46E769C05F8CQ40028889-77798B7A-474F-474F-B6A8-6C82BE5522A1Q40193370-181CD8C3-6CDA-4524-83DD-975FF336CABDQ40385078-1894E4BA-AB5F-43EF-91E8-8D5BA060A6C1Q40577358-250DF839-8788-4331-BDB9-0AB05FF9BB13Q42733362-6213D12A-D5F8-49FF-AE18-91488F10F953Q44063464-0D473ADD-29A9-4EE7-89DD-230D50F77BFAQ47590638-6ED7EF14-C996-4F85-9427-432C0C05E8FDQ48504535-5C5666DF-1BEB-4E55-8F27-FD5DBB093CBAQ49124404-9CB23944-7304-47B2-8314-A50B6FAEA8B0Q49602304-4D41AEA4-6E1D-438A-A697-D79FE0B74EECQ49998709-027457C0-3777-4CA8-864E-624A63B2B3A3Q53743487-A178B0D3-6722-45F4-AFA7-915F5882C904Q57457329-FCF84EAB-C05A-471E-84A3-8FD369580974Q58565007-67FE4980-F818-42E2-8033-851F70007DF0Q80253508-7E797C9F-1243-43F1-978B-455C9088412AQ81063382-6C6EA201-F50B-45A2-8147-EB98EA1CDA4AQ82836842-1D5BAD54-1AD3-4A89-937F-19EE1BF48F73Q87161812-93B22B2E-CCE4-499B-AAF5-9E0A65211C74Q88773625-C050F1A8-5BFB-43E1-868C-C7007EDE4906Q88906468-87776BDB-6EE4-42E0-85E3-EFCA7061BA52
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ravindra K Rawal
@en
Ravindra K Rawal
@nl
type
label
Ravindra K Rawal
@en
Ravindra K Rawal
@nl
prefLabel
Ravindra K Rawal
@en
Ravindra K Rawal
@nl
P31
P496
0000-0001-9035-3579